由于安全顾虑和谨慎的展望,波士顿科学的丰厚收入错过了投资者的期望,导致股票下降。 Boston Scientific's strong earnings missed investor expectations due to safety concerns and a cautious outlook, causing shares to drop.

波士顿科学报道了超过预期的2025年第四季度收益,调整后的每股收益为0.80美元,收入为5290亿美元,同比增长15.9%. Boston Scientific reported fourth-quarter 2025 earnings that beat expectations, with adjusted EPS of $0.80 and revenue of $5.29 billion, a 15.9% year-over-year increase. 尽管取得了强有力的成果并更新了2026年的指导,但股票急剧下降,原因是前景谨慎,特别是其电子生理部分,对AXIOS系统支架安全问题的持续关切,以及CEOMichael Mahoney大量内部销售。 Despite strong results and updated 2026 guidance, shares dropped sharply due to a cautious outlook, particularly in its electrophysiology segment, ongoing concerns over the AXIOS stent safety issue, and a large insider sale by CEO Michael Mahoney. 美国食品和药物管理局已通知医疗保健提供者停止使用受影响的AXIOS支架,此前报告有167人严重受伤,3人死亡. The FDA has notified healthcare providers to stop using affected AXIOS stents after 167 serious injuries and three deaths were reported.